Curis, Inc. (NASDAQ:CRIS) Short Interest Up 148.9% in August

Posted by Geri Gentry on Aug 30th, 2026

Curis, Inc. (NASDAQ:CRIS – Get Free Report) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 324,276 shares, an increase of 148.9% from the July 30th total of 130,308 shares. Based on an average daily volume of 481,898 shares, the days-to-cover ratio is currently 0.7 days. Currently, 16.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CRIS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Zacks Research lowered shares of Curis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Curis in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Curis currently has an average rating of “Reduce” and an average target price of $43.00.

Read Our Latest Report on Curis

Curis Price Performance

CRIS stock opened at $1.49 on Friday. The company has a fifty day moving average price of $4.45 and a 200 day moving average price of $10.56. Curis has a 12 month low of $1.40 and a 12 month high of $39.00. The company has a market cap of $3.11 million, a price-to-earnings ratio of -0.10 and a beta of 3.13.

Curis (NASDAQ:CRIS – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 2,365.94%. As a group, analysts anticipate that Curis will post -24.23 earnings per share for the current year.

Hedge Funds Weigh In On Curis

A number of hedge funds and other institutional investors have recently made changes to their positions in CRIS. Squarepoint Ops LLC raised its stake in Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Curis in the fourth quarter valued at approximately $26,000. Maverick Capital Ltd. increased its holdings in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the period. Finally, Focused Wealth Management Inc increased its holdings in shares of Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 49,900 shares during the period. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

(Get Free Report)

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.